Antiphospholipid syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
[[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials showed: | [[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials showed: | ||
* no benefit from high compared to low intensity warfarin<ref name="pmid 13679527">{{cite journal| author=Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J et al.| title=A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. | journal=N Engl J Med | year= 2003 | volume= 349 | issue= 12 | pages= 1133-8 | pmid= 13679527 | doi=10.1056/NEJMoa035241 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13679527 }} [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15122858 Review in: ACP J Club. 2004 Mar-Apr;140(2):38] </ref><ref name="pmid15869575">{{cite journal| author=Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J et al.| title=A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). | journal=J Thromb Haemost | year= 2005 | volume= 3 | issue= 5 | pages= 848-53 | pmid=15869575 | doi=10.1111/j.1538-7836.2005.01340.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15869575 }} </ref> | * no benefit from high compared to low intensity warfarin<ref name="pmid 13679527">{{cite journal| author=Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J et al.| title=A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. | journal=N Engl J Med | year= 2003 | volume= 349 | issue= 12 | pages= 1133-8 | pmid= 13679527 | doi=10.1056/NEJMoa035241 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13679527 }} [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15122858 Review in: ACP J Club. 2004 Mar-Apr;140(2):38] </ref><ref name="pmid15869575">{{cite journal| author=Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J et al.| title=A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). | journal=J Thromb Haemost | year= 2005 | volume= 3 | issue= 5 | pages= 848-53 | pmid=15869575 | doi=10.1111/j.1538-7836.2005.01340.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15869575 }} </ref> | ||
A [[systematic review]] has summarized the research.<ref name="pmid18050167">{{cite journal| author=Ruiz-Irastorza G, Hunt BJ, Khamashta MA| title=A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. | journal=Arthritis Rheum | year= 2007 | volume= 57 | issue= 8 | pages= 1487-95 | pmid=18050167 | doi=10.1002/art.23109 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18050167 }} </ref> | |||
==References== | ==References== | ||
Revision as of 02:59, 27 April 2017
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome secondary prevention |
|
Risk calculators and risk factors for Antiphospholipid syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Secondary Prevention
Randomized controlled trials have addressed the secondary prevention of thromboses. These trials showed:
A systematic review has summarized the research.[3]
References
- ↑ Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J; et al. (2003). "A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome". N Engl J Med. 349 (12): 1133–8. doi:10.1056/NEJMoa035241. PMID 13679527. Review in: ACP J Club. 2004 Mar-Apr;140(2):38
- ↑ Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J; et al. (2005). "A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)". J Thromb Haemost. 3 (5): 848–53. doi:10.1111/j.1538-7836.2005.01340.x. PMID 15869575.
- ↑ Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007). "A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies". Arthritis Rheum. 57 (8): 1487–95. doi:10.1002/art.23109. PMID 18050167.